FBRX Company Profile and Key Details

FBRX has shown sold momentum, gaining 37.25% over the past week and 98.31% over the past quarter, though year-to-date performance is up 29.15%. Short-term trend indicators are bearishly aligned (SMA20 34.97%, SMA50 73.82%, SMA200 150.56%). The stock’s 14-day RSI is 77.93 (overbought), while the ATR of 2.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -1.28% below its high and over 498.57% above its low. Average 10-day trading volume of 275.99 thousand shares is significantly above the 3-month average of 114.91 thousand, indicating heightened recent market interest.

Forte Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.63. This means the shares are trading above this model’s fair value.

Forte Biosciences, Inc. has 12.43 million shares outstanding. The public float is 10.22 million shares, elevated short interest at 1.25% of float. This equals 128.75 thousand shares. The short ratio is 2.4 days. Institutional investors hold 89.92% of the float. Insiders own 4.96%. Oliveira Steven Michael holds 2.87 million shares, Wagner Paul A. has 1.82 million shares and Hasnain Faheem has 241.72 thousand shares.

Forte Biosciences, Inc. generated EPS of -$4.44 over the past year. Five-year average earnings growth is 24.08%. Wall Street analysts project EPS growth of 29.15% annually over the next five years. The latest quarter delivered EPS of -$0.99. The next quarter is forecast at -$1.18. Next year's EPS is expected at -$8.62. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $75.00 to $61.00. The high target offers 155.71% upside. The low target suggests 107.98% downside. The mean target is $64.00. This offers 118.21% upside. Forte Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -4.45%. The prior quarter beat by -20.66%. Over the last six quarters, Apple has recorded several small beats. These include 68.75% in August 14, 2024.

Forte Biosciences, Inc. (NASDAQ:FBRX) shares are up 29.15% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Forte Biosciences, Inc. trading at a premium to the broader market with a P/E of -9.12. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $49.27, suggesting 67.98% upside. Our AI forecast model points to short-term strength (12.17% over two weeks), a medium-term rise (0.55% over three months), and a longer-term loss (-8.56% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Forte Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.17%, with price expected at $32.90 by January 05, 2026, within a range of $31.36 to $34.56 3-Month Outlook: Projected rise of 0.55%, reaching $29.49 by March 20, 2026, with a range of $28.98 to $30.04. 1-Year Outlook: Projected loss of -8.56%, with price at $26.82 by December 22, 2026, within a range of $25.13 to $28.75.

Forte Biosciences, Inc. trades at a P/E ratio of -9.12, slightly below the S&P 500 average, with a price-to-sales ratio of 8742.46 and a price-to-book ratio of 5.61 trading at moderately above to book value. The P/FCF stands at -7.45, also below market averages.

Forte Biosciences, Inc. (NASDAQ:FBRX) closed at $26.64 USD, losing -$2.68 (-9.15%) from the previous close of $29.33. The stock is currently mid-range between its 52-week high and low $4.90 and $31.27. With a market capitalization of about $333.78 million, Forte Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~3.25). Key stats such as the average daily volume over the past year has been around 120.71 thousand shares, trading with heavier-than-usual volume. Headquartered in Dallas, TX, Forte Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul A. Wagner, the company employs approximately 14 people and listed since April 13, 2017. Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.